期刊文献+

慢性肾功能不全肾脏保护治疗研究进展 被引量:2

下载PDF
导出
摘要 各种原因引起的慢性肾脏疾病最终进行性地发展为终末期肾衰.尽管肾脏替代治疗方法的成功应用挽救了大量患者的生命,但巨额医疗费用仍构成社会和家庭沉重的经济负担.因此,如何延缓慢性肾病的进展一直是肾病工作者所面临的挑战.随着近年来对肾脏纤维化机制研究的深入和循证医学的发展,人们对如何才能延缓慢性肾功能不全的发生取得了不少新的共识.本文略述影响肾脏病进展的有关因素,并根据近年来随机对照研究(Randomized controlled trial,RCT)的结果,介绍可能具有肾脏保护意义的治疗方案.一级推荐方案基于已得到前瞻性、随机、双盲、有安慰剂对照的大规模临床试验验证;二级推荐方案则虽有较好的临床设计,但样本量可能较小,仍有待进一步积累经验;三级推荐方案则指一般性临床观察或基础实验的结果,尚需严格临床设计和进一步深入研究. #
出处 《江苏医药》 CAS CSCD 北大核心 2002年第4期293-295,共3页 Jiangsu Medical Journal
  • 相关文献

参考文献16

  • 1[1]Romero F,Rodriguez-Iturbe B,Parra G,et al.Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats.Kidney Int,1999,55:945-955.
  • 2[2]Abbate M,Zoja C,Rottoli D,et al.Antiproteinuric therapy while preventing the abnormal protein trafficc in proximal tubule abrogates protein-and complement-dependent interstitial inflammation in experimental renal disease.J Am Soc Nephrol,1999,10:804-813.
  • 3[3]Mezzano S,Drognett M,Burgos E,et al.Overexpression of chemokines,fibrogenic cytokines,and myofibroblasts in human membranous nephropathy.Kidney int,2000,57:147-158.
  • 4[4]Brenner B,Taal M.Renoprotective benefits of RAS inhibition:From ACEi to angiotensin Ⅱ antagonists.Kidney Int,2000,57.1803-1817.
  • 5[5]Remuzzi G,Ruggenenti P,Benigni A.Understanding the nature of renal disease progression:In proteinuric nephropathies enhanced glomerular protein traffic contributes to interstitial inflammation and renal scarring.Kidney Int,1997,51:2-15.
  • 6[6]Fogo A.The role of angiotensin Ⅱ and plasminogen activator inhibitor-1 in progressive glomerulosclerosis.Am J Kidney Dis,2000,135:179-188.
  • 7[7]Leehey DJ,Singh AK,Alavi N,et al.Role of angiotensin Ⅱ in diabetic nephropathy.Kidney Int,2000,58(Suppl 77):93-98.
  • 8[8]Hebert LA,Greene T,Levey A,et al.High urine volume (UV) and how urine osmolality(Uosm)are risk factors for faster progression of renal disease(RD),especially in polycystic kidney disease(PKD) patients.J Am Soc Nephrol,2000,11:148A.
  • 9[9]Oda H,Keane W.Recent advances in statins and the kidney.Kidney Int,1999,56(Suppl):2-5.
  • 10[10]Hebert LA,Wilmer WA,Falkenhain ME,et al.Renoprotection:One or many therapies? Kidney Int,2001,59:1211-1226.

同被引文献11

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部